Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply
Lancet Oncol
.
2018 Jan;19(1):e2.
doi: 10.1016/S1470-2045(17)30920-8.
Authors
Meletios A Dimopoulos
1
,
Amy S Kimball
2
Affiliations
1
School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece. Electronic address: mdimop@med.uoa.gr.
2
Amgen, Thousand Oaks, CA, USA.
PMID:
29304357
DOI:
10.1016/S1470-2045(17)30920-8
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Multiple Myeloma*
Neoplasm Recurrence, Local*
Oligopeptides
Proteasome Inhibitors
Recurrence
Substances
Oligopeptides
Proteasome Inhibitors
carfilzomib